Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CLK3 | P49761 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | DNM2 | P50570 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362805 | 0.86 | NOS2 (0.41) | NOS2FLT3MAP4K4HPGDMALT1 | |
| SCHEMBL14924060 | 0.78 | FLT3 (0.39) | FLT3HPGDMALT1CYP2C19DNM2 | |
| SCHEMBL17573454 | 0.77 | NOS2 (0.56) | NOS2MAP4K4CYP2C19DNM2 | |
| SCHEMBL19008154 | 0.76 | MAP4K4 (0.44) | NOS2FLT3MAP4K4HPGD | |
| SCHEMBL18483348 | 0.76 | NOS2 (0.45) | NOS2MAP4K4CYP2C19DNM2 | |
| SCHEMBL18485039 | 0.76 | NOS2 (0.51) | NOS2MAP4K4CYP2C19CLK2CLK3 | |
| SCHEMBL15301101 | 0.76 | NOS2 (0.45) | NOS2FLT3MAP4K4CYP2C19DNM2 | |
| SCHEMBL13436332 | 0.75 | KDR (0.41) | FLT3HPGDCYP2C19DNM2EGFR | |
| SCHEMBL12648603 | 0.75 | HPGD (0.47) | FLT3HPGDMALT1CYP2C19EGFR | |
| SCHEMBL18474534 | 0.75 | NOS2 (0.53) | NOS2MAP4K4CYP2C19DNM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10329309-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190119276-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2019-04-25 | — | — | US | disclosed |
| US-10231956-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-10202377-B2 | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-08-10 | — | — | US | disclosed |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2017-08-03 | — | — | US | disclosed |
| US-9546185-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9540398-B2 | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475825-B2 | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-17 | — | — | US | disclosed |
| US-20160068551-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | NOS2 2481/4885FLT3 1898/4885MAP4K4 551/4885 |
| US-20170224697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NOS2 2515/4885FLT3 1591/4885MAP4K4 452/4885 |
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NOS2 2512/4885FLT3 1520/4885MAP4K4 441/4885 |
| US-20160068548-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | NOS2 2644/4885FLT3 1380/4885MAP4K4 487/4885 |
| US-10329309-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | NOS2 3025/4885FLT3 1472/4885MAP4K4 273/4885 |
| US-10202377-B2 | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | NOS2 2347/4885FLT3 1456/4885MAP4K4 416/4885 |
| US-10231956-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | NOS2 2623/4885FLT3 1915/4885MAP4K4 616/4885 |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NOS2 1633/4885FLT3 981/4885MAP4K4 371/4885 |
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | NOS2 1798/4885FLT3 1266/4885MAP4K4 945/4885 |
| US-10226453-B2 | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | NOS2 2340/4885FLT3 1559/4885MAP4K4 431/4885 |
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT3, WNT1, WNT3A | NOS2 2487/4885FLT3 1846/4885MAP4K4 699/4885 |
| US-20160068551-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | NOS2 2652/4885FLT3 1436/4885MAP4K4 489/4885 |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NOS2 1767/4885FLT3 1009/4885MAP4K4 424/4885 |
| US-10285983-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof | WNT1, WNT3A, WNT3 | NOS2 2469/4885FLT3 1940/4885MAP4K4 671/4885 |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | NOS2 2644/4885FLT3 1380/4885MAP4K4 487/4885 |
| US-20190119276-A1 | 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | NOS2 2347/4885FLT3 1456/4885MAP4K4 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.